Advancing a New Generation
of Immunomodulatory Therapies
Laurentide is developing a novel class of NOD2 agonists designed to unlock the therapeutic potential of innate immunity while avoiding the inflammatory limitations of previous approaches. Our platform is being evaluated across multiple disease areas with the goal of delivering transformative treatments for patients with significant unmet medical needs.
Meet The Team
Laurentide is led by accomplished pharmaceutical, biotech, and scientific leaders with decades of experience advancing innovative therapeutics from discovery to commercialization. Their expertise spans drug development, diagnostics, regulatory strategy, and company building.
Horace Nalle | Vice President
Worked on Merck teams that delivered finasteride, simvastatin, ivermectin and eprinomectin. Former CEO of Merck’s multinational avian genetics company; head of legal and regulatory affairs for Merck’s Merial joint venture.
Professor Emeritus, Auburn University College of Veterinary Medicine. Developed and patented fluorescent probe real-time PCR platform diagnostic technology which has nation-wide leadership in diagnostics of Coronavirus infections of companion animals.
Bernhard Kaltenboeck | CSO
Peter Selover | President
Ex-Merck. Worked on ivermectin, eprinomectin. Formerly President and COO, Sage Veterinary Imaging. Formerly CEO, Exubrion Therapeutics Inc. Head of Global Business Development and Corporate Strategy at Merial, a Merck joint venture.